Head and neck squamous cell carcinoma: a potential therapeutic target for the Wnt signaling pathway

Wnt-mediated signal transduction processes regulate basic processes that determine the functionality or dysfunction of numerous cell types. [17] Specifically, Wnt signaling is a critical regulator of embryonic development and the creation of embryonic cell patterns, as well as the differentiation, proliferation, invasion, polarity, and apoptosis of cells in adult organisms. [18, 19] Disorders of the Wnt signaling can result in various diseases, including cancer and osteoporosis. [20, 21]

To date, at least three different intracellular Wnt signaling pathways have been described; (1) the canonical Wnt/β-catenin signaling pathway, (2) the non-canonical pathways Wnt/PCP (planar cell polarity), and (3) the Wnt/Ca²⁺ signaling pathway. [22] Common to all three pathways are the Wnt proteins, which function as ligands to specific cell surface receptors (Frizzled receptors or Fzds), which trigger intracellular signaling cascades (Fig. 1). The term “canonical Wnts” came from the observation that strongly transforming Wnts transmit signals via β-catenin. [23] At first, it was assumed that all other Wnts signaled via β-catenin-independent signaling pathways and hence were termed “non-canonical Wnts.” [24] However, the canonical Wnt3a can also signal independent of β-catenin by activating Rho and Rho-kinase. [25] In addition, under certain conditions, the non-canonical Wnt5a activates both a β-catenin-dependent and a β-catenin-independent signaling pathway. [26] Consequently, the classic distinction between canonical and non-canonical Wnts can no longer be strictly maintained.

The canonical Wnt/β-catenin signaling pathway primarily regulates the developmental trajectory of cells and the invasiveness and proliferation potential of CSCs. Binding of Wnts to Fzd receptors destabilizes a degradation complex that initiates the breakdown of β-catenin typically. Intracellular β-catenin consequently accumulates and translocates to the cell nucleus and acts as a transcription factor for various Wnt/β-catenin target genes. [16]

The two non-canonical signal pathways cannot be completely separated from one another. Although both pathways have been extensively studied in Drosophila and Xenopus, little is known about the function of these pathways in mammals [27]. It is known that the Wnt/PCP pathway participates in the control of cell polarity and cell movement during gastrulation. [28] In the Wnt/PCP signaling pathway, Wnt-Fzd binding activates disheveled (Dvl). Activated Dvl, in turn, can transmit the signal in two independent ways. [22] This is how Daam1 enables the complex formation of Dvl and Rho, a G protein, followed by the activation of Rho kinase (RhoK) via Rac, another G protein, Dvl leads in parallel to the activation of JNK (JUN N-terminal kinase). [29]

In the Wnt/Ca²⁺ signaling pathway, Wnt-Fzd binding leads to an increased intracellular Ca²⁺ concentration and activates heterotrimeric G proteins, which in turn activate phospholipase C and phosphodiesterase. [30] The high intracellular Ca²⁺ and activated G proteins also activate the calcium/calmodulin-dependent protein kinase II (CaMKII) and the protein kinase C. [31] It is suspected that the Wnt/Ca²⁺ signaling pathway regulates cell proliferation and migration and also functions to inhibit the Wnt/β-catenin pathway. CamKII and TAK1- activate NLK mitogen-activated protein kinase (NLK-MAPK), which then phosphorylates the T-cell factor (TCF) and thereby prevents the binding of the β-catenin/TCF complex to the DNA and thus prevents transcription. [32]

The genetic changes predispose to tumor initiation and progression can occur as relatively small sequence changes to the DNA or chromosomal deviations. [33] The sequence changes affect two classes of genes: the proto-oncogenes and the tumor suppressor genes. [34]

Proto-oncogenes code for proteins that stimulate cell proliferation or progression through the cell cycle. They are converted into oncogenes by amplification of the gene locus, chromosomal translocation, or point mutations, i.e., to activated forms (gain of function), which results in uncontrolled growth of the cells. [35] The mutations in the proto-oncogenes are dominant, which means that the mutation in one of the two alleles is sufficient for the activation of the proto-oncogene. [36] Today, more than 100 known proto-oncoproteins have been described, including growth factors (e.g., PDGF, Wnt-1), their receptors (e.g., EGF receptors), proteins of signal transduction (e.g., Ras proteins, Src kinase), and transcription factors (e.g., c-Jun, c-Fos, c-Myc). [37]

Tumor suppressor genes, in contrast, have an inhibitory effect on cell growth, [38] and thus mutations that impair tumor suppressor function predispose to unregulated cell growth (i.e., cancer). Tumor suppressor gene function may be altered following faulty chromosome or chromatid division during cell division, mitotic recombination, or due to point mutations or deletions. [39] However, the functioning of both tumor suppressor gene alleles must be lost before tumorigenesis occurs; [40] this is referred to as a “loss of heterozygosity” (LOH). Some individuals inherited a mutated allele through the germline, and are thus at an increased risk for LOH and developing cancer. For example, individuals with familial adenomatous polyposis (FAP) syndrome are born with a mutated APC gene and show increased risk of colon cancer. [41] An alternative mechanism of tumor suppressor gene inactivation is epigenetic modification. Various studies have shown that the promoters of different tumor suppressor genes are often methylated in tumors but are free of methylation in healthy tissues. [42] The methylation of the DNA affects 5’-CG-3’ dinucleotides (CpG), which are located in the promoter regions of the genes, [43] and methylation is thus involved in the regulation of gene expression and chromosome condensation. [44] Today, about 30 tumor suppressor genes with different functions are known, including APC, PTEN, SASH1, and p21CIP1/WAF1. [45] One of the most extensively studied tumor suppressor genes is p53, which is reported to be mutated in 50% of all cancer cells. p53 functions to either block the cell cycle or induce apoptosis, and is a transcription factor with an important role in maintaining genomic integrity, hence its name the “guardian of the genome.” [46]

In addition to the classic oncogenes and tumor suppressor genes, there is a large number of additional “tumor genes” that act as modulators of tumor development or that play an essential role in clinical practice as diagnostic and prognostic tumor markers. [47] The chromosomal aberrations lead to aneuploidies — deviations from the normal diploid chromosome set. The changes can affect both the number of chromosomes and the structure of the chromosomes and lead to chromosomal instability (CIN). [48] Genetic instability within the cell can also arise at the nucleotide sequence level (MIN, microsatellite instability). In this case, the tumor cell chromosome set is usually diploid. [49] Furthermore, gene function can also be modified at an epigenetic level, which recent research has increasingly highlighted. [50]

Cancer is not a single disease, but a term for many different types of disease. It is a genetic disease that is based on the uncontrolled growth of specific cells. Cancer is now the second leading cause of death after cardiovascular disease in western countries and the third leading cause of adult deaths in developing countries. [51] Tumor formation is a multi-stage process in which the physiological control of cell proliferation, cell differentiation, and cell–cell interactions are gradually lost. [52] Apart from the inherited forms, most tumors are caused by somatic mutations. [53] The majority of tumors are presumably monoclonal, meaning they arise from a single cell through the accumulation of several genetic and epigenetic changes through proliferation and clonal selection. [54] Tumors start as benign growths of cells maintained in differentiated states exhibition organization to their tissue architecture. As tumorigenesis progresses, additional genetic changes accumulate and lead to the formation of a malignant tumor comprised of poorly differentiated cells, which acquired the ability to penetrate the neighboring tissues and metastasize to distant organs. [55] Six changes in the physiology of the cell define the malignant phenotype: (1) independence from growth-promoting signals, (2) insensitivity to growth-inhibiting signals, (3) resistance to apoptosis, (4) unlimited multiplication potential, (5) persistent angiogenesis, and (6) ability to invade tissue and metastasize. [56]

The Wnt/β-catenin signaling regulates the development and function of many tissues and organs throughout embryonic development and in adult life. [57, 58] The Wnt pathways also interact with many other important signaling pathways, such as the transforming growth factor-β(TGF-β)/Bmp-, Fgf-, Notch-, and hedgehog signaling pathways, which influence each other either in series or in parallel. [19, 59] Even at a very early stage of embryonic development, before gastrulation, Wnt β-catenin signaling is critical for the induction of the mesoderm and the direction the correct formation of the embryonic body axis, [19] as highlighted by experiments where injection of Wnt agonists (Lithium Chloride or Wnt1 mRNA) induced a second body axis in Xenopus embryos. [60] The Wnt/β-catenin signaling pathway is also essential for the development of the primitive endoderm, formation of the head region, and development of many organs, as highlighted by various mouse models. [61] Activation of the Wnt/β-catenin signaling pathway is also necessary to maintain the pluripotency of embryonic stem (ES) cells and for the process of reprogramming differentiated fibroblasts into pluripotent stem cells (iPS). [62]

In certain organs, such as the pituitary gland, dorsal spinal cord, and bone, the Wnt/β-catenin pathway controls the formation, maintenance, and/or specification of progenitor cells. [63] For example, β-catenin/LEF/TCF induces the expression of Pitx2 in the pituitary gland, which is responsible for the formation of Pit1-expressing progenitor cells. [64] During bone development, β-catenin controls the differentiation of osteo-chondrogenic progenitor cells into osteoblasts. [65] The importance of the maintenance of progenitor cells is also observed in the development of the dorsal spinal cord, [63] where Wnt/β-catenin signaling activation promotes the proliferation of Olig3-expressing progenitor cells and to differentiate excess Foxd3 and Isl1/2-expressing interneurons (dI2 and 3 regions). [66] In contrast, the 0 mutation of β-catenin leads to the absence of progenitor cells expressing Olig3, and the loss of Olig3 prevents the formation of dI2- and dI3 neurons. [67] The combination of Olig3 null mutation and Stabilization of β-catenin causes the loss of the dI2 and dI3 neurons and the increase in Lbx1-expressing neurons (dI4-dI6) while maintaining the proliferative effect on the progenitor cells. [68] These results indicate that Wnt/β-catenin in the dorsal spinal cord is important for the formation and maintenance of Olig3- expressing progenitor cells, but not for differentiation into dI2 and dI3 neurons. [68]

In continuously renewing tissues and organs, the Wnt/β-catenin signaling pathway is responsible for the self-renewal of multipotent tissue stem cells. [69, 70] The intestinal stem cells of the intestinal crypts which continually renew the intestinal epithelium require active Wnt/β-catenin signaling for their proliferative function. [71] Newly formed intestinal cells lose the ability to divide, and the Wnt/β-catenin signaling pathway is switched off as they differentiate into terminal cells. [16] However, mutations that result in permanent activation of the Wnt pathway (e.g., involving APC or β-catenin genes) lead to the development of intestinal polyps, characteristic of early stages of colon cancer. [72] On the other hand, in the case of degenerative diseases of the intestinal mucosa, such as Crohn’s disease, there is assumed to be insufficient Wnt/β-catenin activity. [73]

The skin is another organ that continuously renews throughout life. In embryology, Wnt signaling directs the embryonic ectoderm to differentiate into the epithelium by promoting production of keratin and blocking fibroblast growth factor (FGR). [74] Wnt signaling also inducts formation of skin appendages, especially hair follicles, by orchestrating dynamic singaling between the epidermis and dermis. [75] In adult life, Wnt/β-catenin signaling continues to control hair follicle cycling by coordinating the differentiation of follicular stem cells into hair cells in the bulges of the hair follicle. [76] Within hair follicle stem cells, β-catenin is found within the nucleus during anagen (growth phase), but in the cell membrane during telogen (rest phase), and is thus activation of the Wnt pathway is thought to induce the onset of anagen from telogen. [77] Wnt signaling is then further thought to control cell fate within hair follicles. [78] In addition, Wnt/β-catenin is inhibited by the Bmp signaling pathway during the hair cycle — an important criterion for the oscillating renewal and differentiation of the hair follicle stem cells. [79] The signal pathway can induce the development of hair follicle tumors. It could also be shown that cancer stem cells from ras-induced epidermal tumors require active β-catenin for their self-maintenance, which illustrates the great importance of Wnt/β-catenin for the cancer stem cells of the skin. [80] β-catenin is also involved in epidermal proliferation and maintenance of the epidermal stem cell population, as shown in lineage-tracing work in mice. [81, 82] However, interestingly, loss of β-catenin leads to hair loss but has little impact on the integrity of the epidermis. [83] Wnt/β-catenin signaling also helps to orchestrate cutaneous wound healing. In vitro work has shown that human keloid keratinocytes stimulate fibroblasts to secrete R-Spondin2, a Wnt agonist which promotes epidermal proliferation and is thought to lead to the thickened epidermis characteristic of keloid scars. [84] Further work has also shown that TGF-β, a potent regulator of fibrosis, induces activation of β-catenin within dermal fibroblasts, and β-catenin staining is increased in hypertrophic scars and keloid, compared to normal skin. [85] Regarding skin cancer, and specifically SSCs, chromosomes containing WNT and FZD genes are amplified in SSCs in genomic hybridization studies. [86] Messenger RNA levels of Wnt ligands and receptors are increased, and levels of Wnt inhibitors are decreased, further implicating role for Wnt activation in SSC development. [87‐89]

Together, these findings highlight the critical roles of the canonical Wnt signaling pathway in cell regulation in normal functioning and in the development of cancer through altering the regulation of cell expansion and survival of mature cells and stem cells by their direct and/or indirect target genes (Table 1).

Head and neck tumors are treated with surgery, radiotherapy, and chemotherapy. [90] Early-stage cancers are often resected entirely with adjuvant radiotherapy and/or without chemotherapy. Cancer too large to be removed can be debulked and are typically treated with a combination of radiotherapy and chemotherapy. Progress in all three therapeutic areas has been small and the average 5-year survival for patients with head and neck cancer remains at 61%. [91]

Although numerous Wnt receptors and Wnt signaling components are highly expressed in head and neck cancers, [13] there has been hesitation to target β-catenin therapeutically due to its structural role in apical junctions (AJs) and its functional role in CSC self-renewal. [16, 70] However, numerous Wnt inhibitors have been investigated for their antitumor effects in both preclinical and clinical trials. [92] The most promising candidates are inhibitors of porcupine, an acyl-transferase and critical protein in the Wnt/β-catenin cascade. For example, the porcupine inhibitor LGK974 can disrupt HNSCC growth and reduce distant metastases. [93, 94] Recent insight into the specific function of β-catenin within the cell nucleus, however, has supported its potential as a druggable target; [95] antibodies which target Wnt-1 and inhibit cell proliferation can decrease tumor burden, [12, 96] and β-catenin/CBP axis inhibitors can intercept oncogenic activities in the tumor niche. Axitinib is a small-molecular inhibitor of nuclear β-catenin which works by stabilizing ubiquitin ligase SHPRH (SNF2, histone linker, PHD, and RNIG finger domaincontaining helicase), and thus decreasing the availability of nuclear β-catenin. [97] The association of β-catenin with fibrosis and immune cell depletion suggests that targeting the β-catenin-CBP interaction will have intratumoral inhibitory effects (Fig. 2). It is likely that targeting oncogenic pathways in combination with Wnt/β-catenin signaling may be more effective than monotherapies and standard radiation therapy/chemotherapy for the treatment of HNSCC. For example, combining β-catenin/CBP axis inhibitors with immune checkpoint blockades may effectively deplete aggressive CSCs and promote anticancer immune cell function.[98]